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Abstract One key area of protein kinase research is the iden-
ti¢cation of cognate substrates. The search for substrates is
hampered by problems in unambiguously assigning substrates
to a particular kinase in vitro and in vivo. One solution to
this impasse is to engineer the kinase of interest to accept an
ATP analogue which is orthogonal (unable to ¢t into the ATP
binding site) for the wild-type enzyme and the majority of other
kinases. The acceptance of structurally modi¢ed, Q-32P-labelled,
nucleotide analogue by active site-modi¢ed kinase can provide a
unique handle by which the direct substrates of any particular
kinase can be displayed in crude mixtures or cell lysates. We
have taken this approach with the serine/threonine kinase Raf-1,
which plays an essential role in the transduction of stimuli
through the RasCRafCMEKCERK/MAP kinase cascade.
This cascade plays essential roles in proliferation, di¡erentiation
and apoptosis. Here we detail the mutagenesis strategy for the
ATP binding pocket of Raf-1, such that it can utilise an N6-
substituted ATP analogue. We show that these mutations do not
alter the substrate speci¢city and signal transduction through
Raf-1. We screen a library of analogues to identify which are
orthogonal for Raf-1, and show that mutant Raf-1 can utilise
the orthogonal analogue N6(2-phenethyl) ATP in vitro to phos-
phorylate its currently only accepted substrate MEK. Impor-
tantly we show that our approach can be used to tag putative
direct substrates of Raf-1 kinase with 32P-N6(2-phenethyl) ATP
in cell lysates.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
It has been estimated that the mammalian genome encodes
518 putative protein kinase genes, which correspond to 1.7%
of all human genes [1]. Kinases play essential roles in the
communication of external stimuli into the cell by regulating
the cell cycle and many other essential processes. The impor-
tance of kinases in cell regulation is underscored by the fact
that 47% of all kinase genes map to disease loci or cancer
amplicons [1].
The key challenge in the study of any one kinase is to
identify how the kinase is activated and regulated, where the
kinase is located within the cell, and what its e¡ectors (sub-
strates) are. The identi¢cation of kinase substrates has proved
to be remarkably di⁄cult due to several factors: the large
number of kinases; the organisation of kinases into multipro-
tein complexes that often contain several kinases; the di⁄-
culty of rigorously demonstrating that a particular kinase
has been biochemically puri¢ed from other contaminating ki-
nases; the relaxed substrate speci¢city demonstrated by many
kinases in vitro; the overlapping substrate speci¢cities of
many kinases; and the common catalytic requirement of
ATP for all kinases.
Shokat and colleagues have developed a new method for
identifying kinase substrates, using orthogonal ATP ana-
logues. In their studies with the v-Src tyrosine kinase [2^5],
the Shokat group used a site-directed mutagenesis approach
to modify the ATP binding pocket of v-Src to accept an ATP
analogue with a bulky adduct at the N6 position of the purine
ring. This analogue was orthogonal for wild-type v-Src and
other kinases. To engineer v-Src to accept N6(benzyl) ATP the
Src protein crystal structure was used to identify amino acids
in close proximity to the N6 position in the ATP^enzyme
complex [3]. Proximal residues were then mutated to contain
smaller side chains, thus creating an ATP binding pocket that
allowed N6(benzyl) ATP to bind. The power of this approach
was demonstrated by using the mutant v-Src and N6(benzyl)
ATP to identify several new v-Src substrates, initially in cell
lysate labelling experiments and then con¢rmed by in vitro
kinase reactions [5].
We have chosen to apply this approach to the serine/threo-
nine kinase Raf-1, which lacks a solved crystal structure, but
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is distantly related to Src. Raf kinases are the entry point to
the archetypical extracellular signal-regulated kinase/mitogen-
activated protein (ERK/MAP) kinase cascade, which regulates
many fundamental cellular processes by integrating external
growth factor signals into distinct biological responses. Typi-
cally, Raf-1 activation is initiated by binding to activated Ras
which triggers a complex series of posttranslational modi¢ca-
tions and changes in protein interactions that co-operate to
activate Raf-1. Activated Raf-1 in turn activates MAP kinase/
ERK kinase (MEK) or MAP kinase kinase by direct phos-
phorylation. MEK phosphorylates ERK or MAP kinase re-
sulting in its activation. This signaling unit plays key roles
in proliferation, di¡erentiation and apoptosis (for a recent
review see [6]). The Raf family consists of three kinases,
A-Raf, B-Raf and Raf-1. Raf-1 is ubiquitously expressed
and the most thoroughly studied member of the family.
A-Raf and B-Raf show tissue-speci¢c expression, although
improved detection techniques have recently revealed that
they are more widely expressed than originally suspected [7].
The only generally accepted substrate for Raf is MEK,
which has two homologues, MEK1 and MEK2. However,
there is increasing evidence that Raf-1 can also signal outside
this established signaling unit in a MEK-independent fashion
(for review see [8]). The most convincing evidence comes from
Raf-1 knock-out mice [9,10]. In these studies, Raf-1 expres-
sion was abolished completely, and resulted in embryonic le-
thality. Interestingly, the phosphorylation of MEK appeared
to be normal in Raf-13=3 ¢broblasts upon stimulation with
growth factors and the Raf-13=3 cells had normal prolifera-
tive capacity. Despite the apparent normal regulatory phos-
phorylation of MEK, Raf-13=3 cells had an increased propen-
sity towards apoptosis. This suggests that Raf-1 can function
independent of MEK and that this signaling pathway im-
pinges on the regulation of apoptosis.
In the present study, we have mutated Raf-1 in its ATP
binding pocket, to create a mutant that can utilise an orthog-
onal ATP analogue, N6(2-phenethyl) ATP. We have based
our choice of mutations on a three-dimensional homology
model of Raf-1 and sequence alignment to kinases with
known crystal structures. We demonstrate that the mutations
in the ATP binding pocket do not a¡ect Raf-1 signaling or the
ability of Raf-1 to phosphorylate MEK. We show that mutant
Raf-1 can utilise N6(2-phenethyl) ATP to phosphorylate
MEK and tag putative direct Raf-1 substrates in cell free
lysates.
2. Materials and methods
2.1. Cloning and mutagenesis
The mutations were constructed by polymerase chain reaction
(PCR) with two sets of oligonucleotides as described previously [19].
PCR was performed with the Pwo polymerase (Boehringer Mann-
heim) using Raf-1 cDNA as the template. Ampli¢ed fragments were
restricted with EcoRI and BamHI and cloned into the FLAG-CMV-2
expression vector (Sigma). All ampli¢ed fragments were sequenced in
their entirety. For expression in insect Sf9 cells mutated Raf-1 cDNAs
were cloned into the baculovirus vector pAcGHLT-C (Pharmacia).
Recombinant baculovirus was generated by cotransfection of Sf9 cells
with linear baculovirus and recombinant transfer vector DNAs.
2.2. Protein expression and puri¢cation
FLAG-tagged Raf-1 proteins were expressed by transient transfec-
tion in COS-1 cells using E¡ectene (Promega). Thirty-six hours after
transfection, the cells were washed with phosphate-bu¡ered saline and
serum-starved overnight. The following morning the cells were stimu-
lated with 12-O-tetradecanoylphorbol 13-acetate (1 Wg/ml) for 20 min.
Cells were lysed in TBST (20 mM Tris^HCl pH 7.4, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100) supplemented with protease and
phosphatase inhibitors. Extracts were cleared by centrifugation and
the over-expressed proteins puri¢ed by immunoprecipitation over-
night with the M2 FLAG monoclonal antibody (Sigma).
Glutathione S-transferase (GST)-tagged Raf-1 proteins were ex-
pressed in insect Sf9 cells and were activated by co-expression with
Ras and Src baculovirus as described [20]. Infected Sf9 cells were
collected and washed 44 h post infection. Cells were lysed using
TBST and the lysates cleared by centrifugation. The over-expressed
Raf proteins were puri¢ed using glutathione-Sepharose beads (Amer-
sham Pharmacia Biotech). GST-tagged kinase-dead MEK was ex-
pressed in Sf9 cells and puri¢ed as described above. Additionally,
GST-MEK was eluted from the glutathione-Sepharose using compe-
tition with glutathione, and the protein eluent dialysed to remove
residual glutathione.
2.3. Raf-1 kinase assays
In vitro kinase assays were performed in a 30 Wl volume in Raf-1
kinase bu¡er (20 mM Tris^HCl pH 7.4, 20 mM NaCl, 10 mM MgCl2,
1 mM dithiothreitol) in the presence of 350 ng GST-MEK and 100
WM ATP or ATP analogue, as indicated in the text. The addition of
similar quantities of Raf-1 and mutants was monitored by immuno-
blotting and/or Coomassie staining. Reactions were incubated at 32‡C
for 20 min and terminated with the addition of 5ULaemmli sample
bu¡er. Reactions were separated on 10% sodium dodecyl sulfate
(SDS)^polyacrylamide gels and blotted onto polyvinylidene di£uoride
membrane (Millipore). MEK phosphorylation was detected by prob-
ing with the MEK phosphospeci¢c antibody 9121 (Cell Signaling),
and MEK levels were checked using MEK antibody 9122 (Cell Signal-
ing). To control for the amount of input Raf-1 proteins, all mem-
branes were subsequently probed with the cRaf-1 monoclonal anti-
body (Transduction Laboratories).
In situ kinase assays were carried out in a volume of 100 Wl using
desalted serum-starved COS-1 lysates prepared as described in [17].
Desalted lysate was mixed with activated Raf-1 or mutants, 100 WM
ATP or analogue, 5 mM magnesium chloride in Raf kinase assay
bu¡er (50 mM Tris pH 7.5, 150 mM sodium chloride, 5 mM
EGTA, 5 mM magnesium chloride). Reactions were incubated at
32‡C for 1 h and terminated by adding 5ULaemmli sample bu¡er.
The reactions were separated by SDS^polyacrylamide gel electropho-
resis (PAGE), blotted and probed as described in the ¢gure legends.
Radiolabelling of lysates was carried out in a volume of 100 Wl by
mixing desalted serum-starved COS-1 lysate, GST-Raf-1 or GST-Raf-
1 mutants, 100 WM cold ATP, and 0.7 MBq of [32P]ATP or [32P]N6-
(2-phenethyl) ATP in Raf kinase assay bu¡er. Reactions were incu-
bated at 32‡C for 30 min and terminated by adding 5ULaemmli
sample bu¡er. The reactions were separated by large-format SDS^
PAGE, blotted and exposed to ¢lm at 370‡C. The blots were probed
as described in the ¢gure legends.
2.4. Synthesis of ATP analogues
N6-modi¢ed adenosine analogues were synthesised by re£uxing
6-chloropurine riboside (Aldrich) with the corresponding amines in
ethanol overnight [21]. N6-substituted ATP analogues were synthe-
sised by the method of Hecht and Kozarich [22] as described in [2].
The radiolabelled analogue was puri¢ed on DEAE (A-25) Sephadex
(0.1^1 M triethylammonium bicarbonate bu¡er pH 7.5) and the tri-
phosphate was identi¢ed by co-injection of the radiolabelled material
with an authentic sample of N6 ATP analogue on a strong anion
exchange high performance liquid chromatography column (5^750
mM ammonium phosphate pH 3.9 in 10 min at 0.5 ml/min).
2.5. Homology modelling
The tertiary structure for Raf-1 was modelled by means of homol-
ogy modelling [23]. For the purpose, the homology modelling pro-
gram MODELLER was employed [12]. In homology modelling, a
homologous structure is used as a template for the unknown struc-
ture. MODELLER obtains the three-dimensional model of the un-
known protein by satisfying spatial restraints in the form of proba-
bility density functions (pdfs) derived from the alignment of the
unknown structure with one or more homologous structures. The
pdfs restrain CK^CK distances, main-chain N^O distances, as well as
main-chain and side-chain dihedral angles. The optimisation is carried
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out by the variable target method that applies the conjugate gradient
algorithm to positions of all non-hydrogen atoms. The initial model
generated by MODELLER is further optimised by constrained energy
minimisation with all the backbone atoms ¢xed using the program X-
PLOR [24].
2.6. Reporter gene assays
Reporter gene assays were done as previously described [25].
Brie£y, COS-1 cells were transfected using E¡ectene (Promega),
with 1 Wg DNA per well in a six-well plate. The DNA included an
AP-1 luciferase reporter construct, an activated truncated Raf-1
(BXB) construct and a L-galactosidase construct. Each sample was
done in triplicate. Cells were harvested 48 h post transfection and
lysed using reporter assay lysis bu¡er (Promega). Lysates were as-
sayed for luciferase activity (reagents from Promega) and for L-galac-
tosidase activity. Each data point was adjusted for transfection e⁄-
ciency (using L-galactosidase assay results) and is an average of three
wells.
2.7. Radiolabelling of cell lysates for 2D gel electrophoresis
Rat-1 S100 cytosolic extracts (40 Wg) were mixed with 10 mM
MgCl2, 100 WM ATP, 10 mM KCl, 0.5 mM EDTA, 20 WCi of
[32P]ATP or [32P]N6(2-phenethyl) ATP and 100 WM ATP. FLAG-
tagged Raf-1, Raf-1 TAFL, or Raf-1 TAFLGA was expressed in
COS cells and immunopuri¢ed as described above. Raf-1 proteins
were added and the reactions were incubated at room temperature
for 30 min. Kinase reactions were clari¢ed by PlusOne 2-D Clean-
up Kit (Amersham Biosciences) and resuspended in rehydration bu¡er
(8 M urea, 2% Triton X-100, IPG bu¡er (pH 3^10 NL), 0.002%
bromophenol blue) for the ¢rst dimensional isoelectric focusing
(IEF). IEFs with Immobiline Drystrip (7 cm, pH 3^10 NL, Amersham
Biosciences) were performed at 5000 V for 3 h using Ettan1IPG-
phor1 Isoelectric Focusing System (Amersham Biosciences). IEF
strips were equilibrated in SDS equilibration bu¡er (50 mM Tris,
6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue) for 15
min before loading onto 12% SDS^PAGE. Gels were dried and were
subject to autoradiography using Kodak X-Omat AR ¢lm.
3. Results
3.1. The Raf-1 kinase domain: mutagenesis strategy based on
structure prediction
No crystal structure of the Raf-1 kinase domain has been
determined. Raf-1 is a serine/threonine-speci¢c kinase and its
kinase domain shows highest similarity to Src family tyrosine
kinases [11]. As shown in Fig. 1a, the primary sequence of the
kinase domain of Raf-1 and that of c-Src share 33% identity
and 53% homology. Therefore, we based our mutagenesis
strategy on the strategy utilised by Shokat et al. [2] to obtain
v-Src mutants that accept orthogonal ATP analogues. These
authors replaced the isoleucine at position 338 in v-Src with a
glycine to create an ATP binding pocket that could accom-
modate N6(benzyl) ATP. A subsequent mutational analysis of
v-Src showed that Ile338 was the key determinant of speci¢c-
Fig. 1. Mutagenesis strategy and modelling of the Raf-1 ATP binding pocket. a: Alignment of the primary sequence of the kinase domains of
Raf-1 and c-Src (PDB accession number 2SRC). Threonine 338 in c-Src and 421 in Raf-1 are indicated. b: Homology model of Raf-1 with
bound ATP. The peptide is shown in a cartoon representation. The three mutated residues T421, F475 and G485 and their side chains are
shown as is ATP which has been modelled into the binding site. c: Alignment of Raf-1, v-Src, Cdk2 and PKA, showing the sites targeted for
mutagenesis in Raf-1 in this study. d: Schematic representation of the constructs used in this study.
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ity for N6-substituted ATP analogues [4]. These results have
been con¢rmed in mutational studies of Thr339 of Fyn, which
occupies the position corresponding to Ile338 of v-Src [4].
Ile338 is a threonine in c-Src that corresponds to Thr421 in
Raf-1. Therefore, we changed Thr421 to alanine or glycine.
Although mutation at position Thr421 did confer orthogonal
ATP analogue speci¢city on Raf-1 mutant kinase, it resulted
in a low catalytic e⁄ciency (data not shown).
In order to further improve the catalytic e⁄ciency of the
Thr421 Raf-1 mutants, additional targets for mutation were
sought. To aid this search we modelled the Raf-1 kinase do-
main by means of homology modelling using the program
MODELLER [12] based on the 1.5 AS resolution crystal struc-
ture of human tyrosine protein kinase c-Src (PDB accession
number 2SRC [13]). The modelled three-dimensional structure
for the Raf-1 peptide includes residues 331^607. The nucleo-
tide ATP was placed into the protein analogous to its position
in the crystal structure of c-Src [13]. The complex structure of
Raf-1 with ATP was then optimised with molecular mechanics
energy minimisation. The ¢nal model of Raf-1, as analysed by
PROCHECK [14], has all the residues in the allowed regions
of Ramachandran plot and an acceptable overall geometry.
The full details of the Raf-1 kinase domain model will be
presented in a separate communication.
The ATP binding pocket in the modelled three-dimensional
structure (Fig. 1b) and sequence alignment of Raf-1 to other
kinases (Fig. 1c) guided our selection of residues for site-di-
rected mutagenesis. The goal was to enlarge the binding pock-
et of the adenine moiety of ATP so that a large substituent at
the N6 position can be accommodated spatially. Thr421
stands out in terms of geometric proximity to the N6 atom
of adenine. The closest atom to atom distance between the
side chain of Thr421 and the N6 amino group of ATP is 4.8 AS .
This geometric proximity of Thr421 in the modelled Raf-1
structure is consistent with known crystal structures of two
serine/threonine kinases, cAMP-dependent protein kinase
(PKA) and cyclin-dependent protein kinase 2 (Cdk2), and
three tyrosine kinases in the Src family (Src, Hck and Lck).
Analysis of these structures revealed that in all cases the side
chains of residues homologous to Thr338 in c-Src or Met120
in PKA are within a 5 AS sphere of the N6 amino group of
ATP [2]. In Fig. 1c, the primary sequence of Raf-1 is aligned
with those of PKA, Cdk2 and v-Src. It shows that the residue
Thr421 of Raf-1 is aligned to the corresponding residues in
v-Src (Ile338) or PKA (Met120).
A careful inspection of the Raf-1 modelled structure re-
vealed other residues with side chains that are in close prox-
imity to the adenine base of ATP. For instance, Leu406 is
located only 5 AS away from the N6 amino group of ATP.
Therefore, we mutated Leu406 to alanine. However, the re-
sulting mutant kinase showed very low catalytic e⁄ciency
(data not shown). Phe475 is in close geometric proximity to
the adenine base with a closest atom to atom distance of 3.5 AS .
Interestingly, in our modelled structure (Fig. 1b) Phe475 is
positioned at the entrance of the ATP binding pocket. We
reasoned that the low catalytic e⁄ciency of the Thr421 Raf-
1 mutants could be due to the bulky Phe475 residue restricting
the access of the bulky substituted ATP analogues to the ATP
binding pocket. A sequence alignment between Raf-1, v-Src,
Cdk2 and PKA (Fig. 1c) showed that Phe475 of Raf-1 corre-
sponds to a leucine in the other three kinases. Therefore, we
mutated Phe475 to leucine, creating a double mutant (T421A
and F475L). Hereafter, this double mutation is denoted Raf-
TAFL. We also engineered a triple mutant by mutating an
additional residue, Gly485, to alanine. The rationale behind
this mutation was to better emulate the structure of the v-Src
kinase. As seen in the sequence alignment between Raf-1 and
v-Src (Fig. 1c), Gly485 of Raf-1 corresponds to Ala403 in
v-Src. The G485A mutation enhances the similarity between
Raf-1 and v-Src. This triple mutant (T421A, F475L and
G485A) is denoted Raf-TAFLGA throughout the text.
The following studies characterise these mutants in more
detail. In addition to full-length Raf-1 these mutations were
also introduced into the isolated Raf-1 kinase domain, BXB
(Fig. 1d). BXB contains a deletion of the N-terminal regula-
tory domain and is functionally equivalent to v-Raf [15].
3.2. In vitro and in vivo activities of mutated Raf-1 proteins
The main purpose of generating these Raf-1 mutants was to
develop them as tools for the identi¢cation of physiological
substrates. Therefore, it was important to show that the mu-
tations did not alter the biochemical or biological properties
of the Raf-1 kinase. First, we examined the ability of the
mutant kinases to phosphorylate the MEK substrate (Fig.
2a). Wild-type Raf-1 and the di¡erent mutants were tagged
at the amino-terminus with the FLAG epitope, over-expressed
by transient transfection in COS-1 cells, and puri¢ed by im-
munoa⁄nity chromatography. The kinase activities of the pu-
ri¢ed proteins were determined using recombinant MEK as
the substrate. MEK phosphorylation was detected with an
antibody directed against the phosphorylated form of MEK.
This antibody detects MEK only when it is phosphorylated
on the activating serine residues Ser217 and Ser221. FLAG-
tagged wild-type Raf-1 isolated from serum-deprived cells had
very low activity (data not shown). Raf-1 kinase activity was
substantially stimulated upon treatment with epidermal
growth factor (Fig. 2a, lane 1). The speci¢city of the kinase
activity was demonstrated by the observation that almost no
measurable activity was detected in preparations of kinase-
dead Raf-1 K375W (lane 2). Under these conditions the ac-
tivity of the Raf-1 TAFL and TAFLGA kinases was only
slightly reduced relative to wild-type Raf-1 (compare lane 1
with lanes 4 and 5). In contrast, the activity of the Raf-1 TA
kinase was still detectable, but at a signi¢cantly reduced level
(lane 3). For that reason only the double and triple mutants,
Raf-1 TAFL and TAFLGA kinases, were selected for further
experiments.
The above results could be explained by a reduced interac-
tion of the mutants with MEK or ATP. However, kinase-dead
Raf-1 is very e⁄cient in interacting with MEK and actually
acts as a substrate trap, presumably because it can bind sub-
strate but not phosphorylate it (data not shown). Therefore,
we examined the ability of the mutant kinases to utilise ATP
(Fig. 2c). The wild-type, TAFL and TAFLGA Raf-1 proteins
displayed a comparable KM for ATP (3.3 WM, 6.0 WM, and
1.2 WM, respectively). The KM of Raf-1 for ATP was previ-
ously reported as 11.6 WM [16]. This is in agreement with our
measurements, given that Force et al. [16] used a di¡erent
kinase assay and a di¡erently tagged version of the Raf-1
protein. The widening of the ATP binding pocket to accom-
modate N6-substituted ATP analogues usually does not pre-
clude the binding of ATP [2]. While this is often viewed as an
unwanted e¡ect, it has the advantage that such mutant ki-
nases can function normally when expressed in cells. This is
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important as kinase-dead mutants often behave as dominant
negative mutants that sequester activators and substrates.
To measure the e¡ects of the mutations on the biological
activity of Raf-1, we made use of the well documented obser-
vation that the AP-1 transcription factor is one of its main
intracellular e¡ectors. In order to ensure that AP-1 activation
was elicited by the transfected Raf-1 protein and not endog-
enous Raf-1, we incorporated the Raf-1 TAFL double muta-
tions and Raf-1 TAFLGA triple mutations into a constitu-
tively active form of Raf-1, BXB (Fig. 1b). BXB or its
mutated derivatives were transiently expressed in COS-1 cells
in the presence of a luciferase reporter gene whose expression
was dependent on AP-1 activity. The control was an equiva-
lent reporter plasmid without AP-1 binding sites. The data
(Fig. 2b) are presented as proportions of wild-type Raf-BXB
activity. AP-1 reporter activity of the double and triple mu-
tants was similar to BXB, although a little reduced. In fact,
the reduction is proportionally the same as the reduction in
MEK phosphorylation seen in Fig. 2a. Activation of the re-
porter was AP-1-speci¢c, since a reporter without AP-1 bind-
ing sites (AP-1 control) was not activated by any of the BXB
constructs. Similarly, Raf-BXB constructs with TAFL or
TAFLGA mutations were capable of conferring anchorage-
independent growth in soft agar colony assays (data not
shown).
Taken together, these results con¢rm that the mutations
introduced into the ATP binding site do not signi¢cantly af-
fect the biochemical, biological properties, and the substrate
speci¢city of Raf-1. Our next step was to identify an optimal
orthogonal ATP analogue for these mutants.
3.3. Speci¢city of wild-type and mutated Raf-1 proteins for
ATP analogues
To ¢nd the optimal ATP analogue for the double and triple
Raf-1 mutants, we screened a panel of N6-substituted ATP
analogues which included aliphatic and aromatic substituents
(Fig. 3a). This assay employed immunoprecipitated FLAG-
tagged Raf-1 and mutant proteins, and recombinant kinase-
dead MEK. The e⁄cacy of each ATP analogue was assessed
by blotting for phosphorylated MEK (Fig. 3b). Wild-type
Fig. 2. Mutations in the ATP binding pocket do not a¡ect the biochemical or biological properties of Raf-1. a: In vitro kinase assays. Raf-1,
Raf-K375W (kinase-negative mutant) and ATP binding site mutants were expressed in COS-1 cells as described in Section 2. Raf-1 proteins
were immunoprecipitated and incubated with puri¢ed recombinant MEK protein. Reactions were separated by SDS^PAGE and blotted. The
blots were probed with anti-phospho-MEK (upper panel), anti-MEK (middle panel) and anti-Raf-1 (lower panel). b: AP-1 luciferase reporter
assay data. COS-1 cells were transfected with the indicated plasmids and L-galactosidase expression vector. 4UAP-1 Luc contains a quadrupli-
cate AP-1 binding site in its promoter, 0UAP-1 Luc is the corresponding control plasmid. Luciferase expression was adjusted for transfection
e⁄ciency using L-galactosidase activity. Data are shown as fraction of wild-type Raf-BXB activity. Each data point is representative of four
separate experiments performed in triplicate. c: KM(ATP) determination for Raf-1 and mutants. Assays were done as described in Section 2
and data are presented as Lineweaver^Burk plots.
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Raf-1 and the double and triple mutants showed a similar
usage of ATP. Surprisingly, we found that wild-type Raf-1
could utilise a number of N6-substituted ATP analogues in-
cluding N6(ethoxy) ATP, N6(2-methylbutyl) ATP as well as
N6(benzyl) ATP. The double and triple mutants showed sim-
ilar activity with regard to the analogues as the wild-type
enzyme, with the exception of N6(2-phenethyl) ATP. In this
assay N6(2-phenethyl) ATP emerged as the most reasonable
orthogonal ATP analogue. Both Raf-TAFL and Raf-TAFL-
GA could utilise this analogue, but wild-type Raf-1 was
clearly compromised. The double mutant, Raf-1 TAFL, had
an approximately twofold better kinase activity towards MEK
with N6(2-phenethyl) ATP than the triple mutant. To inves-
tigate whether these di¡erences in MEK substrate phosphor-
ylation can be explained by a di¡erential utilisation of N6(2-
phenethyl) ATP the KM values of the Raf-1 TAFL and
TAFLGA mutants for N6(2-phenethyl) ATP were determined
(Fig. 3c). The KM was 50 WM for Raf-1 TAFL and 100 WM
for Raf-1 TAFLGA. This twofold di¡erence closely correlates
with the ability to phosphorylate MEK. Thus, these mutations
make substrate phosphorylation by Raf dependent on the
ability to use the corresponding ATP analogue without dis-
turbing the interaction with protein substrates. Of similar im-
portance was the ¢nding that wild-type Raf-1 had an at least
10-fold or greater KM for N6(2-phenethyl) ATP than the mu-
tants.
3.4. In vitro labelling of cell extracts with
[32P]N6(2-phenethyl) ATP
As judged by the above results the Raf TAFL and Raf
TAFLGA mutants appeared to be suitable tools for the iden-
ti¢cation of new Raf-1 substrates. Unfortunately, N6(2-phe-
nethyl) ATP was not cell-permeable precluding in vivo label-
ling. Therefore, we used a cell-free system, termed KESTREL,
that was devised to identify new substrates for protein ki-
nases [17]. This system uses crude cell lysates that are desalted
using a PD-10 ion exchange column to remove small mole-
cules including ATP. This guarantees that the only source of
ATP is exogenously added ATP. The kinase of interest is
added as a puri¢ed protein along with [Q-32P]ATP in order
to allow the phosphorylation of substrates in the lysate [17].
In contrast to most other protein kinases Raf-1 only phos-
phorylates native MEK ^ Raf-1 does not phosphorylate de-
natured MEK or peptide substrates [16]. Therefore, to vali-
date the KESTREL system we determined if the Raf TAFL
mutant could phosphorylate MEK in desalted lysate prepared
from COS-1 cells. The desalted lysates were incubated with
ATP or N6(2-phenethyl) ATP plus puri¢ed recombinant
GST-tagged Raf-1 proteins produced in Sf9 insect cells. Phos-
phorylated MEK was detected by a phosphospeci¢c anti-
body (Fig. 4a). These results show that Raf and the Raf
TAFL mutant could utilise ATP with similar e⁄ciency to
phosphorylate MEK in crude cell lysates. The Raf TAFL
Fig. 3. Identi¢cation of ATP analogue utilised by Raf-1 ATP binding site mutants. a: The panel of ATP analogues used in screen with Raf-1
and mutants. b: In vitro kinase assays with immunoprecipitated Raf-1 and mutants and puri¢ed MEK as substrate, with the ATP analogues
shown in panel a. Kinase assays were done as described in Section 2 and phosphorylated MEK was visualised by immunoblotting with anti-
phospho-MEK antibody. c: KM(N6(2-phenethyl) ATP) determination for Raf-1 and mutants. Data are presented as Lineweaver^Burk plots.
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mutant could also readily utilise N6(2-phenethyl) ATP to
phosphorylate MEK. The wild-type Raf-1 protein was much
less e⁄cient although a low level of MEK phosphorylation
was observed. The results con¢rm that the KESTREL cell-
free system preserves protein/substrate folding and hence is
suitable for the identi¢cation of new candidates for Raf-1
substrates.
We next used radiolabelled [32P]N6(2-phenethyl) ATP to
label desalted COS-1 lysates in the presence of wild-type
Raf-1 or Raf TAFL (Fig. 4b). Surprisingly, we observed a
rather high background of kinase activity in lysates incubated
with [32P]N6(2-phenethyl) ATP alone in the absence of added
Raf proteins. This was unexpected and we tried various con-
ditions to reduce this background. The lowest background
was obtained when radiolabeling with [32P]N6(2-phenethyl)
ATP was carried out in the presence of 100 WM cold ATP
(compare lanes 1^5 with 6^10). The excess cold ATP presum-
ably quenches kinases in the lysate which are promiscuous for
ATP substrate. The addition of recombinant Raf-1 proteins
did result in the phosphorylation of MEK as indicated by the
use of a Raf-1 inhibitor, ZM33672, to assure that phosphor-
ylations were indeed Raf-1-dependent. A radiolabelled band
at the position of MEK (as indicated by the arrow in Fig. 4b
and the lower panel) was observed when the lysate was incu-
bated with Raf TAFL and N6(2-phenethyl) [32P]ATP, but
abolished in the presence of ZM33672. The identity of the
radiolabelled band was subsequently con¢rmed by immuno-
blotting (data not shown). Similar results were obtained with
TAFLGA mutants (data not shown). Thus, both TAFL and
TAFLGA mutants can facilitate the identi¢cation of Raf-1
substrates.
Despite numerous attempts and di¡erent regimens we could
not further reduce the background phosphorylation. There-
fore, we investigated whether a higher resolution gel technique
such as 2D gel electrophoresis could reveal di¡erences in sub-
strate phosphorylation between Raf-1 and the Raf-1 mutants
in the presence of [32P]N6(2-phenethyl) ATP. For this purpose
we prepared cytosolic extracts from serum-starved Rat-1 cells.
Serum starvation will render many cellular kinases inactive
and thus reduces the background. Puri¢ed recombinant Raf-
1 or Raf-1 TAFLGA kinases were added to the Rat-1 extract
and incubated with [32P]N6(2-phenethyl) ATP and 100 WM
cold ATP. The proteins were analysed by 2D gel electropho-
resis. The higher resolution of this method revealed additional
phosphorylated proteins (marked by arrows), which are
present exclusively or at much higher abundance in extracts
labelled with [32P]N6(2-phenethyl) ATP and TAFLGA mutant
kinase (Fig. 4c). Identical results were obtained with Raf-1
TAFL (data not shown). These results strongly suggest that
Raf-1 has more substrates in addition to MEK. The phos-
phorylated proteins could be detected by autoradiography,
but their detection by various protein stains was unreliable.
This indicates low abundance and has so far hindered their
identi¢cation.
Fig. 4. Labelling of MEK and putative new substrates by Raf-1 mutants and N6(2-phenethyl) ATP in cell lysates. a: Phosphorylation of MEK
in cell lysates by puri¢ed GST-tagged Raf-1 and Raf-1 TAFL in the presence of ATP or N6(2-phenethyl) ATP. Kinase assays were done as de-
scribed in Section 2. Phosphorylated MEK was detected by immunoblotting with an anti-phospho-MEK antibody (upper panel). Total MEK
and added GST-Raf proteins were detected using anti-MEK (middle panel) and anti-Raf-1 (lower panel) antibodies. b: Whole-cell lysate label-
ling with [Q-32P]ATP and [Q-32P]N6(2-phenethyl) ATP. Desalted COS-1 lysates were mixed with puri¢ed GST-tagged Raf-1 or Raf-1 TAFL in
the presence or absence of Raf-1 inhibitor ZM33672 (10 WM) as indicated. 20 WCi of [32P]ATP or [32P]N6(2-phenethyl) ATP and 100 WM ATP
were added. After incubation at room temperature for 30 min samples were separated by SDS^PAGE, blotted and autoradiographed. A short
and a long exposure of the autoradiogram is shown. Arrows indicates the radiolabelled MEK in the lysates. The lower panel is an enlargement
of the region containing phosphorylated MEK. c: 2D gel electrophoresis of kinase reactions using [32P]N6(2-phenethyl) ATP. An in vitro kinase
assay was performed using desalted Rat-1 extract, 20 WCi [32P]N6(2-phenethyl) ATP, 100 WM ATP, and FLAG-tagged Raf-1 or Raf TAFLGA.
Samples were subject to IEF in the ¢rst dimension and SDS^PAGE in the second dimension as indicated. Shown are autoradiograms with dif-
ferentially phosphorylated proteins indicated by arrows.
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4. Discussion
We have carried out a mutagenesis study of the serine/
threonine kinase Raf-1 with the aim of generating a mutant
Raf-1 that can utilise orthogonal ATP analogues while pre-
serving its ability to faithfully phosphorylate its substrate
MEK and to mediate Raf-1-dependent signaling in cells.
Our choice of mutations was based on a successful studies
with v-Src [2,4,5], which was mutated to utilise N6(benzyl)
ATP. The choice of mutations in the Shokat group studies
was guided by homology to kinases with known structures,
followed by a re¢nement round of mutagenesis and screening
of a library of ATP analogues. A similar strategy was adopted
here. As the three-dimensional structure of Raf-1 is still un-
known, we developed a homology model of Raf-1 based on
the 1.5 AS resolution crystal structure of v-Src. The homology
model along with sequence alignment to other kinases with
known crystal structures was used to identify residues in geo-
metric proximity of the adenine base in the ATP binding
pocket. Those proximal amino acids were Thr421 (analogous
to v-Src Ile338), Phe475 (analogous to v-Src Leu398) and
Gly485 (analogous to v-Src Ala405). They were mutated to
alanine, leucine and alanine respectively, to mirror the studies
with v-Src relative to position 421 in Raf-1, and to mirror the
v-Src ATP binding site for positions 475 and 485. The initial
stage of our studies involved a Raf-1 T421A single mutant.
However, this single mutation had a very low catalytic activity
(data not shown). Thus, additional double and triple muta-
tions were made. The data presented in this study compare the
catalytic properties of wild-type Raf-1 with the double mutant
Raf-1 T421A F475L (TAFL) and triple mutant Raf-1 T421A
F475L G485A (TAFLGA). We show that both the double
and triple mutant of Raf-1 proteins can utilise N6(2-pheneth-
yl) ATP, which is orthogonal for wild-type Raf-1.
While it is not currently possible to predict with certainty
an optimal mutant^analogue combination, we show here that
this can be achieved by an iterative process of optimisation. In
our experience there are two key requirements for performing
the optimisation process in a timely fashion: a non-radioac-
tive kinase assay for the phosphotransfer reaction and a large
library of ATP analogues. We have found probing with a
phospho-speci¢c antibody against substrate(s) to be a rapid
and sensitive assay of phosphotransfer. For the tyrosine ki-
nase family of enzymes probing with phospho-tyrosine anti-
bodies can be adapted for this purpose [4]. This avoids the
otherwise necessary use of radiolabelled ATP analogues in the
early engineering stage of a study such as this. To aid the
search for an optimal analogue, we synthesised a library of
over 30 analogues, which include a variety of aliphatic, cyclic,
and aromatic substituents.
The Raf-1 TAFL and TAFLGA mutants utilised several
ATP analogues with varying e⁄ciency. These results suggest
that the mutations do not a¡ect catalysis, but only the a⁄nity
of the enzyme for the ATP analogue. That is, the catalytic
e⁄ciency of any given enzyme^analogue pair is determined
primarily by the a⁄nity of the enzyme for the ATP analogue.
When considered in combination with the data on v-Src
[2,4,5], it is becoming increasingly apparent that the ATP
binding domain is a robust structure whose ATP binding
pocket can be subjected to extensive engineering without af-
fecting the binding of protein substrates. A recent crystal
structure of c-Src complexed with N6(benzyl) ADP showed
that the mutation of the ATP binding pocket does not alter
the phospho-acceptor binding site of the kinase [18]. It is
interesting to note that, although the Raf-1 mutations have
been made to mirror the v-Src mutant, the behaviour of the
mutant Raf-1 and mutant v-Src proteins towards the panel of
analogues was di¡erent. While N6(benzyl) ATP was not ac-
cepted by wild-type v-Src, it was accepted by wild-type Raf-1
(Fig. 3). The N6 substituent had to be enlarged to 2-phenethyl,
which is bulkier than benzyl, in order to obtain an ATP ana-
logue not accepted by wild-type Raf-1 and yet capable of
being accepted by a mutant form. Thus, Raf-1 may have an
intrinsically larger ATP binding pocket than v-Src.
Our results also suggest that the guiding principle of ‘bulki-
ness’ in redesigning ATP binding pockets of protein kinases is
likely to be an oversimpli¢cation. Speci¢c contacts between
amino acid side chains and the ATP substituent play an in-
creasingly important role as the interaction between the pro-
tein and the analogue is optimised. For example, while v-Src
accepted both N6(cyclopentyl) ATP and N6(benzyl) ATP, the
Raf-1 double and triple mutants accepted only N6(benzyl)
ATP and did not accept N6(cyclopentyl) ATP, both of which
are less bulky than N6(2-phenethyl) ATP. Thus, Raf-1 seems
to prefer aromatic N6 substituents and discriminate against
the cyclic aliphatic substituents. A recent study has explored
the shape of the ATP binding pocket of v-Src by engineering
di¡erent N-substituted ATP analogues. This study revealed
that the mutation of Ile338 in v-Src to the smaller Ala or
Gly residues did not create an entirely new ATP binding
pocket, but rather the mutations opened a gate for the N6
substituent on ATP to gain access to an existing pocket in
the ATP binding site [4]. Therefore, a large library of ATP
analogues is crucial for the optimisation and ¢ne tuning of
enzyme^analogue interactions. Our observations show that it
may require more than one mutation and an iterative optimi-
sation process in order to generate suitable mutants that lend
themselves as tools for the discovery and characterisation of
substrates.
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